Integra Lifesciences (IART) AI Stock Analysis

• Market Cap: $966.64M
• Dividend Yield: N/A
• Average Volume (3M): 833.42K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.61
• Revenue Growth: 4.99%
• EPS Growth: -7151.40%
• Country: US
• Employees: 4,396
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): 0.54
• Shares Outstanding: 77,892,110
• 10 Day Avg. Volume: 913,319
• 30 Day Avg. Volume: 833,419
• PEG Ratio: 2.28
• Price to Book (P/B): 1.13
• Price to Sales (P/S): 1.08
• P/FCF Ratio: 69.96
• Enterprise Value/Market Cap: 1.12
• Enterprise Value/Revenue: 0.66
• Enterprise Value/Gross Profit: 1.23
• Enterprise Value/Ebitda: -3.45
• 1Y Price Target: $12.33
• Price Target Upside: -0.64% Downside
• Rating Consensus: Moderate Sell
• Number of Analyst Covering: 6
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 45 Neutral
• Price Target: $11.00 ▼(-11.36% Downside)

Integra Lifesciences' overall stock score is primarily impacted by its financial performance and technical analysis. The company faces significant profitability challenges and bearish technical indicators. Valuation metrics further reflect the company's struggles, with a negative P/E ratio and no dividend yield. Despite some operational efficiencies highlighted in the earnings call, the overall outlook remains cautious.

Positive Factors

Strong Operational Efficiency

Exceeding EPS guidance through operational efficiency and cost management indicates robust internal processes, supporting long-term profitability.

International Revenue Growth

Strong international growth, especially in China, suggests successful global expansion strategies, enhancing market position and revenue diversification.

Improved Manufacturing Yields

Significant improvements in manufacturing efficiency can lead to cost savings and better inventory management, strengthening supply chain resilience.

Negative Factors

Supply Chain Disruptions

Ongoing supply chain issues can hinder product availability and sales, affecting revenue consistency and customer satisfaction over the medium term.

Negative Profit Margins

Sustained negative profit margins indicate operational inefficiencies and financial strain, challenging the company's ability to generate sustainable profits.

Lowered Revenue Guidance

Reduced revenue guidance reflects challenges in meeting market expectations, potentially impacting investor confidence and strategic planning.

Integra Lifesciences Business Overview & Revenue Model

Company Description

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, and general surgery. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as asset management software and support, and after-market services. It also sells approximately 40,000 instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute and chronic wounds; and surgical tissue repair products for hernia repair, peripheral nerve repair and protection, and tendon repair. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.

How the Company Makes Money

Integra LifeSciences generates revenue through the sale of its medical devices and products across several key segments, including neurosurgery, orthopedics, and advanced wound care. The company’s revenue model is primarily based on direct sales to hospitals and healthcare providers, as well as through distribution agreements and partnerships with other medical companies. Key revenue streams include sales of surgical instruments, biologic products, and tissue regeneration solutions. Additionally, Integra benefits from recurring revenue through its implantable devices and consumable products, which are frequently used in surgical procedures. Strategic partnerships and collaborations with healthcare organizations and research institutions also contribute to its earnings by expanding product offerings and market reach.

Integra Lifesciences Financial Statement Overview

Summary

Integra Lifesciences faces significant financial challenges, particularly in profitability and cash flow generation. Despite improvements in leverage, the company needs to address operational inefficiencies and enhance its revenue and profit margins to ensure sustainable growth.

Income Statement

Integra Lifesciences shows a concerning trend in its income statement. The TTM data reveals a negative net profit margin of -30.15%, indicating significant losses. The EBIT and EBITDA margins are also negative, reflecting operational challenges. Despite a slight revenue growth of 1.31% in the TTM, the company's profitability metrics have deteriorated compared to previous years, highlighting a need for strategic adjustments.

Balance Sheet

The balance sheet presents a mixed picture. The debt-to-equity ratio has improved to 0.21 in the TTM, suggesting better leverage management compared to previous years. However, the return on equity is negative at -38.51%, indicating that the company is not generating sufficient returns on shareholders' equity. The equity ratio stands at a moderate level, reflecting a balanced asset structure.

Cash Flow

Cash flow analysis shows challenges in maintaining positive free cash flow growth, with a significant decline of -281.61% in the TTM. The operating cash flow to net income ratio is 0.25, indicating limited cash flow generation relative to net income. However, the free cash flow to net income ratio is relatively strong at 0.78, suggesting some ability to convert earnings into cash.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.64B	1.61B	1.54B	1.56B	1.54B	1.37B
Gross Profit	878.94M	882.06M	884.74M	970.31M	944.64M	851.03M
EBITDA	-313.07M	193.29M	255.96M	384.60M	366.33M	267.93M
Net Income	-495.33M	-6.94M	67.74M	180.55M	169.07M	133.89M
Balance Sheet
Total Assets	3.65B	4.04B	3.78B	3.89B	3.78B	3.62B
Cash, Cash Equivalents and Short-Term Investments	267.88M	273.57M	309.10M	456.66M	513.45M	470.17M
Total Debt	2.01B	1.98B	1.68B	1.63B	1.67B	1.66B
Total Liabilities	2.61B	2.49B	2.19B	2.09B	2.10B	2.10B
Stockholders Equity	1.04B	1.55B	1.59B	1.80B	1.68B	1.51B
Cash Flow
Free Cash Flow	-14.47M	24.96M	73.09M	217.38M	264.35M	139.94M
Operating Cash Flow	89.31M	129.38M	139.96M	264.47M	312.43M	203.83M
Investing Cash Flow	-77.41M	-390.81M	-94.18M	-58.58M	-161.44M	-68.07M
Financing Cash Flow	-3.16M	237.86M	-229.93M	-251.95M	-98.23M	121.63M

Integra Lifesciences Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 12.41
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IART, the sentiment is Negative. The current price of 12.41 is below the 20-day moving average (MA) of 12.76, below the 50-day MA of 12.66, and below the 200-day MA of 13.74, indicating a bearish trend. The MACD of -0.07 indicates Positive momentum. The RSI at 44.43 is Neutral, neither overbought nor oversold. The STOCH value of 25.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IART.

Integra Lifesciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
UFPT	75 Outperform	$2.01B	30.20	18.31%	―	29.47%	23.24%
CNMD	70 Outperform	$1.29B	20.19	6.60%	2.02%	4.69%	-51.57%
AXGN	66 Neutral	$1.43B	-633.06	-1.90%	―	18.72%	85.77%
BVS	64 Neutral	$656.31M	70.61	4.97%	―	1.58%	―
OFIX	55 Neutral	$556.38M	-4.63	-24.60%	―	4.31%	3.26%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
IART	45 Neutral	$966.64M	-1.92	-38.71%	―	4.99%	-7151.40%

Integra Lifesciences Corporate Events

Integra Lifesciences Adopts New Severance Program

On December 11, 2025, Integra LifeSciences announced the adoption of a change in control severance program effective January 1, 2026, for certain executives, including key figures like Lea Knight and Robert T. Davis, Jr. This program, which renews the expiring one, offers severance packages and benefits in the event of employment termination following a company control change by December 31, 2026. The program includes lump sum payments, COBRA premium subsidies, and outplacement services, with provisions to avoid excise tax penalties. The term of the program extends automatically upon a change in control or qualifying termination, impacting the company’s executive retention strategy and stakeholder interests.

The most recent analyst rating on (IART) stock is a Hold with a $11.00 price target. To see the full list of analyst forecasts on Integra Lifesciences stock, see the IART Stock Forecast page.